|
Have You Entered Our Mercedes Giveaway?
You can win. You can win a cruise. A shopping spree. And of course, the grand prize, a 2014 Mercedes-Benz!  Click Here to learn more and find out how to get your tickets.
Tickets are $75 per ticket, $200 for 3, or $300 for 5 tickets.
Two early birds: buy your tickets early to get a shot at also winning:
A cruise
A shopping spree
And you can do it all while helping keep alive critical programs for patients and a highly functional information hub for lupus alive.
Get your tickets now.
|
Information contained in this e-Newsletter should not be considered a substitute for professional diagnosis, treatment or management of S.L.E. and symptoms by a physician.
Missed a previous issue of this e-Newsletter?
You can now view our ARCHIVES.
Editor: Spandan Chakrabarti
|
|
Connect with us on
via "Lupus Online"
|
|
LFNC is an active partner in
|
LFNC's Social Media Program is funded through a generous grant from THE HENRY L. GUENTHER FOUNDATION GEORGE H. SANDY FOUNDATION GLAXOSMITHKLINE |
|
|
|
|
You are receiving this newsletter because you have subscribed or have participated in our programs or events. We respect your time and privacy. If you prefer not to continue receiving the newsletter, you can click on the "safe unsubscribe" button below. We hope, however, that you will opt to remain on our newsletter list for important information and life-saving tips that you or someone you know may benefit from now or in the future.
|
|
DOD Funds 3-Year Clinical Trial for New Lupus Treatment
 Immunomedics, the company that has been developing the new lupus treatment milatuzumab has announced that the Department of Defense has issued a three-year, $1.6 million grant for the drug's clinical trial. The milatuzumab antibody is already in human clinical trials for several forms of cancer, but the DOD grant will allow it to enter human clinical trials as a treatment for lupus. Immunomedics notes that milatuzumab is the only clinical trial application granted by the DOD, out of 44.
Funded by the Peer Reviewed Medical Research Program of the DOD, the clinical trial will evaluate milatuzumab, our proprietary humanized anti-CD74 antibody, in a subcutaneous formulation in patients with lupus. Approximately 30 lupus patients will be recruited at Cedars Sinai Medical Center in Los Angeles, CA, under the direction of Dr. Daniel J. Wallace, the principal clinical investigator of this project.
Read more here. Dr. Wallace is a Board member of the Lupus Research Institute, LFNC's national research partner.
|
|
Two National Lupus Research Organizations Team Up to Identify New Treatments
The Lupus Research Institute - for whom the LFNC is a regional partner - has teamed up with the Alliance for Lupus Research to speed up the process of identifying and making available new lupus treatments.
An initial scan of all of the drugs and treatments available for human use has found approximately 70 existing therapies that have been approved for other conditions -- multiple sclerosis, rheumatoid arthritis, transplant rejection or cancer -- that potentially could be used to treat lupus. The new collaborative project will produce a comprehensive evidence-based analysis to fully document and prioritize each as a potential lupus therapy based on mechanism of action, safety profile, availability, feasibility to carry out a trial in lupus, and likelihood to succeed. A panel of academic and industry experts will review the database and prioritize potential therapies, and approximately 20 candidates are expected to emerge for further study in small focused science-rich clinical trials.
Read more about the collaborative effort here.
|
|
Fall Lupus Medical Conference
C. Michael Neuwelt, MD, Professor of Medicine at UCSF, will headline the conference.
Dr. Neuwelt is a clinical professor of Medicine at the University of California San Francisco, Chief of Rheumatology at Alameda County Medical Center in Oakland and Director of Rheumatology Core Curriculum at St. Mary's Medical Center in San Francisco. He has been challenged and fascinated by Systemic Lupus Erythematosus (SLE) since 1973 during his third year of medical school. This challenge has persisted in his private clinical practice and teaching at a county hospital since 1979. Dr. Neuwelt will discuss latest trends in disease management of lupus and present an update on several lupus research projects he is involved in.
The conference will also feature a presentation on the psychological problems commonly associated with SLE by LFNC Board Member and pain psychology therapist, Sarah S. Goozee, Ph.D.
Date: Saturday, November 9, 2013
Time: 11 am to 4 pm
Venue: Sutter Health Alta Bates Summit Medical Center. 350 Hawthorne Ave, Oakland, CA 94609
Registration: Please register online or complete the form on the back of this flyer and mail or fax it with your payment to the LFNC.
Fee: $50 for California Registered Nurses (5 CEU credits) | $30 for non-credit attendees. Includes refreshments; Current LFNC members are entitled to $10 off the registration fee.
The Lupus Foundation of Northern California wishes to thank the following for their assistance in making this conference possible: Lupus Research Institute and GlaxoSmithKline.
|
|
|
|
|
|
|
